The recently-announced medium-term targets for 2025 are surprisingly ambitious, compelling us to reconsider our stance on the stock. The targets speak giant numbers (14%/15.5% CAGR sales/EBITDA between 2017 and 2025) and reflect a robust outlook for Sartorius’ underlying markets. Biosimilars are expected to play a key role and so are China and the US. We acknowledge management’s optimism and bump up our out-year revenue growth/EBITDA growth rates from 8%/10% to 13.5%/15%. Our reco
05 Mar 2018
Ambitious new medium-term targets reflecting underlying strength
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Ambitious new medium-term targets reflecting underlying strength
Sartorius AG (0NIQ:LON) | 13,825 0 0.0% | Mkt Cap: 10,352m
- Published:
05 Mar 2018 -
Author:
Jyoti Prakash -
Pages:
5
The recently-announced medium-term targets for 2025 are surprisingly ambitious, compelling us to reconsider our stance on the stock. The targets speak giant numbers (14%/15.5% CAGR sales/EBITDA between 2017 and 2025) and reflect a robust outlook for Sartorius’ underlying markets. Biosimilars are expected to play a key role and so are China and the US. We acknowledge management’s optimism and bump up our out-year revenue growth/EBITDA growth rates from 8%/10% to 13.5%/15%. Our reco